De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Daré Bioscience Beheer

Beheer criteriumcontroles 3/4

De CEO Daré Bioscience's is Sabrina Johnson, benoemd in May2015, heeft een ambtstermijn van 9.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.22M, bestaande uit 40.5% salaris en 59.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.94% van de aandelen van het bedrijf, ter waarde $ 259.76K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.3 jaar en 7.3 jaar.

Belangrijke informatie

Sabrina Johnson

Algemeen directeur

US$1.2m

Totale compensatie

Percentage CEO-salaris	40.5%
Dienstverband CEO	9.4yrs
Eigendom CEO	0.9%
Management gemiddelde ambtstermijn	6.3yrs
Gemiddelde ambtstermijn bestuur	7.3yrs

Recente managementupdates

Recent updates

Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms

Oct 17

Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive

Oct 10

Dare Bioscience reports positive progress for cream for female sexual arousal disorder

Aug 29

Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy

Jun 30

Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?

Apr 02

Diving Back Into Daré Bioscience Again

Jan 07

We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully

Nov 26

Daré Bioscience's DARE-BV1 shows positive action in late-stage bacterial vaginosis study

Apr 26

Diving Into Daré Bioscience

Jan 31

Why Daré Bioscience, Inc. (NASDAQ:DARE) Could Be Worth Watching

Dec 22

Dare Bioscience EPS misses by $0.06

Nov 12

Analyse CEO-vergoeding

Hoe is Sabrina Johnson's beloning veranderd ten opzichte van Daré Bioscience's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$7m
Mar 31 2024	n/a	n/a	-US$29m
Dec 31 2023	US$1m	US$495k	-US$30m
Sep 30 2023	n/a	n/a	-US$41m
Jun 30 2023	n/a	n/a	-US$40m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	US$2m	US$466k	-US$31m
Sep 30 2022	n/a	n/a	-US$25m
Jun 30 2022	n/a	n/a	-US$30m
Mar 31 2022	n/a	n/a	-US$40m
Dec 31 2021	US$2m	US$405k	-US$39m
Sep 30 2021	n/a	n/a	-US$38m
Jun 30 2021	n/a	n/a	-US$33m
Mar 31 2021	n/a	n/a	-US$30m
Dec 31 2020	US$835k	US$368k	-US$27m
Sep 30 2020	n/a	n/a	-US$23m
Jun 30 2020	n/a	n/a	-US$19m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$629k	US$335k	-US$15m
Sep 30 2019	n/a	n/a	-US$14m
Jun 30 2019	n/a	n/a	-US$13m
Mar 31 2019	n/a	n/a	-US$12m
Dec 31 2018	US$618k	US$325k	-US$17m
Sep 30 2018	n/a	n/a	-US$23m
Jun 30 2018	n/a	n/a	-US$22m
Mar 31 2018	n/a	n/a	-US$19m
Dec 31 2017	US$291k	US$144k	-US$12m

Compensatie versus markt: De totale vergoeding ($USD 1.22M ) Sabrina } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Sabrina is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Sabrina Johnson (57 yo)

9.4yrs

Tenure

US$1,222,108

Compensatie

Ms. Sabrina Martucci Johnson serves as Director at BIOCOM, Inc. since February 2021. Ms. Johnson Founded Daré Bioscience since 2015 and serves as its Chief Executive Officer and President and is its Princi...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Sabrina Johnson	CEO, President	9.4yrs	US$1.22m	0.94% $ 257.4k
Lisa Walters-Hoffert	Executive Officer	less than a year	US$747.99k	0.43% $ 118.6k
Mark Walters	Vice President of Operations	9.8yrs	geen gegevens	geen gegevens
MarDee Haring-Layton	Chief Accounting Officer	2.5yrs	geen gegevens	geen gegevens
David Friend	Chief Scientific Officer	6.3yrs	geen gegevens	geen gegevens

6.3yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van DARE is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sabrina Johnson	CEO, President	7.3yrs	US$1.22m	0.94% $ 257.4k
William Rastetter	Independent Chairman of the Board	10.8yrs	US$113.89k	0.010% $ 2.8k
Robert Langer	Member of Scientific Advisory Board	5.6yrs	geen gegevens	geen gegevens
Susan Kelley	Independent Director	10yrs	US$78.89k	0% $ 0
Robin Steele	Independent Director	7.3yrs	US$86.39k	0.24% $ 65.8k
Jessica Grossman	Independent Director	6.5yrs	US$83.89k	0% $ 0
Gregory Matz	Independent Director	6.1yrs	US$93.89k	0.00049% $ 134.4

7.3yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van DARE wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.3 jaar).

Daré Bioscience Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Daré Bioscience, Inc., Annual General Meeting, Jun 05, 2024

Daré Bioscience, Inc. Announces the Resignation of Lisa Walters-Hoffert as Chief Financial Officer

Daré Bioscience, Inc. Announces Executive Changes

Daré Bioscience, Inc., Annual General Meeting, Jul 14, 2022

Daré Bioscience, Inc., Annual General Meeting, Jun 23, 2022

Recent updates

Daré Bioscience, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Dare Bioscience, Inc. Announces Publication in Obstetrics & Gynecology of Phase 2B Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder

Daré Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $18.08963 million.

Daré Bioscience, Inc., Annual General Meeting, Jun 05, 2024

Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Daré Bioscience, Inc. Announces the Resignation of Lisa Walters-Hoffert as Chief Financial Officer

Daré Bioscience, Inc. Announces Executive Changes

Daré Bioscience's Common Stock to Be Delisted from Nasdaq Unless the Company Timely Requests A Hearing Before the Nasdaq Hearing Panel

Daré Bioscience's Common Stock to Be Delisted from Nasdaq Unless the Company Timely Requests A Hearing Before the Nasdaq Hearing Panel

Dare Bioscience, Inc. Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the Dare-Pdm1 Phase 1 Clinical Study

Dare Bioscience, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1

Dare Bioscience, Inc. Announces Commencement of Phase 3 Study of Ovaprene, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

New major risk - Revenue and earnings growth

We're A Little Worried About Daré Bioscience's (NASDAQ:DARE) Cash Burn Rate

Daré Bioscience, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Price target decreased by 11% to US$5.33

New major risk - Financial position

New major risk - Revenue size

Daré Bioscience, Inc. Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth

Daré Bioscience Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully

Dare Bioscience, Inc. Announces Additional Positive Data from Exploratory Phase 2b Response Study of Sildenafil Cream, 3.6% in Women

New minor risk - Profitability

Consensus revenue estimates decrease by 18%

Daré Bioscience, Inc. Provides Update on Activities to Support Commercial Launch of XACIATO

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Postmenopausal Women

Dare Bioscience, Inc. Announces Positive Topline Data from the Exploratory Phase 2b Response Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

Consensus revenue estimates increase by 29%, EPS downgraded

No longer forecast to breakeven

Is Daré Bioscience (NASDAQ:DARE) In A Good Position To Invest In Growth?

Price target increased by 13% to US$6.00

Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause

Daré Bioscience, Inc. Announces Positive Pharmacokinetic Results from the DARE-HRT1 Phase 1 / 2 Study

Forecast to breakeven in 2025

Daré Bioscience Receives Non-Compliance Notice From Nasdaq

Consensus revenue estimates fall by 38%

Consensus forecasts updated

Price target decreased to US$5.33

Daré Bioscience, Inc. Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study

Daré Bioscience Announces Subject Screening for Phase 2B Respond Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete

Daré Announces Topline Results of Its Phase 1/2 Clinical Study of Dare-HRT1

Daré rises on positive data from early-to-mid-stage trial of intravaginal ring to treat menopause symptoms

Daré Bioscience, Inc. Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Daré Bioscience rises as company submits application to begin trial of non-hormonal contraceptive

Daré Bioscience Announces Interim Analysis of Phase 2B Respond Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

Dare Bioscience reports positive progress for cream for female sexual arousal disorder

Consensus revenue estimates increase by 24%

No longer forecast to breakeven

Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy

Daré Bioscience, Inc., Annual General Meeting, Jul 14, 2022

Consensus revenue estimates increase by 11%

Daré Bioscience, Inc., Annual General Meeting, Jun 23, 2022

Price target increased to US$8.25

Forecast to breakeven in 2024

Daré Bioscience, Inc. Initiates Phase 1/2 Clinical Study of DARE-HRT1

Consensus revenue estimates increase by 43%

Forecast to breakeven in 2024

Will Daré Bioscience (NASDAQ:DARE) Spend Its Cash Wisely?

Price target increased to US$8.25

No longer forecast to breakeven

Diving Back Into Daré Bioscience Again

Forecast to breakeven in 2024

Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis

We Think Daré Bioscience (NASDAQ:DARE) Needs To Drive Business Growth Carefully

Daré Bioscience, Inc. Announces NIH Grant Award to Support Development of DARE-LARC1

Daré Bioscience, Inc. Initiates Phase 1/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy

Consensus revenue estimates increase to US$5.48m

Daré Bioscience, Inc. Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis

Price target increased to US$6.33